Healthcare / BiotechnologyShanghai
$12.88
-0.32 (-2.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-38.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
39.0x
↑EV/EBITDA
8.7x
↓ROE
8.8%
↑Gross Margin
47.7%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
22.3%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $563.1M · net income $143.7M · FCF $125.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $563.1M | $563.1M | $555.6M | $443.8M | $433.4M |
| Net Income | $143.7M | $143.7M | $124.2M | $91.4M | $64.4M |
| EBITDA | $226.2M | $226.2M | $196.9M | $148.9M | $105.5M |
| EPS | 0.86 | 0.86 | 0.74 | 0.54 | 0.38 |
| Gross Margin | 47.7% | 47.7% | 43.6% | 42.4% | 42.1% |
| Operating Margin | 27.2% | 27.2% | 23.2% | 20.7% | 20.8% |
| Net Margin | 25.5% | 25.5% | 22.4% | 20.6% | 14.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 3.76 | 3.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $125.5M | $125.5M | $-38.6M | $-228.8M | $-73.1M |
| Returns | |||||
| ROE | 8.8% | 8.8% | 8.0% | 6.2% | 4.5% |
| Valuation | |||||
| P/E | 39.03 | 39.03 | 24.11 | 31.67 | 90.56 |
| EV/EBITDA | 8.65 | 8.65 | 14.53 | 17.90 | 50.88 |
| P/B | 1.32 | 1.32 | 1.92 | 1.96 | 4.11 |
| Growth & Yield | |||||
| Revenue Growth | 1.4% | 1.4% | 25.2% | 2.4% | — |
| EPS Growth | 16.2% | 16.2% | 37.0% | 42.1% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.9%
EPS terminal req.
$1.14
Spread vs growth
6.3%
5Y implied EPS CAGR
10.0%
EPS terminal req.
$1.38
Spread vs growth
6.3%
10Y implied EPS CAGR
10.0%
EPS terminal req.
$2.23
Spread vs growth
6.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.5%
Start / end P/E
37.9x → 15.0x
EPS bridge
0.74 → 0.86
Residual
-9.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.